Epcoritamab Monotherapy as Outpatient Treatment for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Interim Results From EPCORE NHL-6

David Andorsky; Adelba Torres Lopez; Rakhee Vaidya; Fernando Vargas Madueno; Sami Ibrahimi; Seema Naik; Mitul Gandhi; Julie Erika Haydu; Bradley Lash; Mark Fesler; John Hrom; Eric H. Lee; Suchitra Sundaram; Kristin Conte; Kojo Osei-Bonsu; Thomas Doerr; Yang Bai; Neha Dixit; Christian W. Eskelund; Alexander P. Boardman; Ralph Boccia; Christina Y. Lee; Jeff P. Sharman

doi:10.1016/j.clml.2026.02.006

Epcoritamab Monotherapy as Outpatient Treatment for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Interim Results From EPCORE NHL-6

David Andorsky
, Adelba Torres Lopez
, Rakhee Vaidya
, Fernando Vargas Madueno
, Sami Ibrahimi
, Seema Naik
, Mitul Gandhi
, Julie Erika Haydu
, Bradley Lash
, Mark Fesler
, John Hrom
, Eric H. Lee
, Suchitra Sundaram
, Kristin Conte
, Kojo Osei-Bonsu
, Thomas Doerr
, Yang Bai
, Neha Dixit
, Christian W. Eskelund
, Alexander P. Boardman

Ralph Boccia, Christina Y. Lee, Jeff P. Sharman

Medical Oncology

Cannon Research Institute at Rocky Mountain Cancer Centers
Hospital Auxilio Mutuo
Wake Forest University
Moffitt Cancer Center
OU Health-Stephenson Cancer Center
Pennsylvania State University
Virginia Cancer Specialists
Massachusetts General Hospital Cancer Center
Lehigh Valley Topper Cancer Institute
St. Luke's Hospital - Chesterfield
Forrest General Hospital
Los Angeles Cancer Network/Compassionate Cancer Care
Icahn School of Medicine at Mount Sinai
AbbVie
Genmab A/S
Memorial Sloan-Kettering Cancer Center
Center for Cancer and Blood Disorders
Willamette Valley Cancer Institute and Research Center

Research output: Contribution to journal › Article › peer-review

Abstract

MicroabstractEPCORE NHL-6 evaluated outpatient administration and monitoring of subcutaneous epcoritamab after the first full dose in 2L+ DLBCL. Epcoritamab was generally well tolerated with nearly all patients successfully monitored in the outpatient setting, highlighting feasibility of outpatient epcoritamab administration and representing an opportunity to advance patient care across academic and community-based centers. Efficacy was consistent with previous 3L+ DLBCL findings.

Original language	English
Journal	Clinical Lymphoma, Myeloma and Leukemia
DOIs	https://doi.org/10.1016/j.clml.2026.02.006
State	Accepted/In press - 2026

Keywords

Clinical trial
DLBCL
epcoritamab
outpatient
relapsed/refractory

Access to Document

10.1016/j.clml.2026.02.006

Cite this

Andorsky, D., Lopez, A. T., Vaidya, R., Madueno, F. V., Ibrahimi, S., Naik, S., Gandhi, M., Haydu, J. E., Lash, B., Fesler, M., Hrom, J., Lee, E. H., Sundaram, S., Conte, K., Osei-Bonsu, K., Doerr, T., Bai, Y., Dixit, N., Eskelund, C. W., ... Sharman, J. P. (Accepted/In press). Epcoritamab Monotherapy as Outpatient Treatment for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Interim Results From EPCORE NHL-6. Clinical Lymphoma, Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2026.02.006

@article{bca6c0a217cf4f4bbdc6be35df8cc820,

title = "Epcoritamab Monotherapy as Outpatient Treatment for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Interim Results From EPCORE NHL-6",

abstract = "MicroabstractEPCORE NHL-6 evaluated outpatient administration and monitoring of subcutaneous epcoritamab after the first full dose in 2L+ DLBCL. Epcoritamab was generally well tolerated with nearly all patients successfully monitored in the outpatient setting, highlighting feasibility of outpatient epcoritamab administration and representing an opportunity to advance patient care across academic and community-based centers. Efficacy was consistent with previous 3L+ DLBCL findings.",

keywords = "Clinical trial, DLBCL, epcoritamab, outpatient, relapsed/refractory",

author = "David Andorsky and Lopez, \{Adelba Torres\} and Rakhee Vaidya and Madueno, \{Fernando Vargas\} and Sami Ibrahimi and Seema Naik and Mitul Gandhi and Haydu, \{Julie Erika\} and Bradley Lash and Mark Fesler and John Hrom and Lee, \{Eric H.\} and Suchitra Sundaram and Kristin Conte and Kojo Osei-Bonsu and Thomas Doerr and Yang Bai and Neha Dixit and Eskelund, \{Christian W.\} and Boardman, \{Alexander P.\} and Ralph Boccia and Lee, \{Christina Y.\} and Sharman, \{Jeff P.\}",

note = "Publisher Copyright: {\textcopyright} 2026 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license. http://creativecommons.org/licenses/by/4.0/",

year = "2026",

doi = "10.1016/j.clml.2026.02.006",

language = "English",

journal = "Clinical Lymphoma, Myeloma and Leukemia",

issn = "2152-2650",

}

Andorsky, D, Lopez, AT, Vaidya, R, Madueno, FV, Ibrahimi, S, Naik, S, Gandhi, M, Haydu, JE, Lash, B, Fesler, M, Hrom, J, Lee, EH, Sundaram, S, Conte, K, Osei-Bonsu, K, Doerr, T, Bai, Y, Dixit, N, Eskelund, CW, Boardman, AP, Boccia, R, Lee, CY & Sharman, JP 2026, 'Epcoritamab Monotherapy as Outpatient Treatment for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Interim Results From EPCORE NHL-6', Clinical Lymphoma, Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2026.02.006

TY - JOUR

T1 - Epcoritamab Monotherapy as Outpatient Treatment for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

T2 - Interim Results From EPCORE NHL-6

AU - Andorsky, David

AU - Lopez, Adelba Torres

AU - Vaidya, Rakhee

AU - Madueno, Fernando Vargas

AU - Ibrahimi, Sami

AU - Naik, Seema

AU - Gandhi, Mitul

AU - Haydu, Julie Erika

AU - Lash, Bradley

AU - Fesler, Mark

AU - Hrom, John

AU - Lee, Eric H.

AU - Sundaram, Suchitra

AU - Conte, Kristin

AU - Osei-Bonsu, Kojo

AU - Doerr, Thomas

AU - Bai, Yang

AU - Dixit, Neha

AU - Eskelund, Christian W.

AU - Boardman, Alexander P.

AU - Boccia, Ralph

AU - Lee, Christina Y.

AU - Sharman, Jeff P.

PY - 2026

Y1 - 2026

N2 - MicroabstractEPCORE NHL-6 evaluated outpatient administration and monitoring of subcutaneous epcoritamab after the first full dose in 2L+ DLBCL. Epcoritamab was generally well tolerated with nearly all patients successfully monitored in the outpatient setting, highlighting feasibility of outpatient epcoritamab administration and representing an opportunity to advance patient care across academic and community-based centers. Efficacy was consistent with previous 3L+ DLBCL findings.

AB - MicroabstractEPCORE NHL-6 evaluated outpatient administration and monitoring of subcutaneous epcoritamab after the first full dose in 2L+ DLBCL. Epcoritamab was generally well tolerated with nearly all patients successfully monitored in the outpatient setting, highlighting feasibility of outpatient epcoritamab administration and representing an opportunity to advance patient care across academic and community-based centers. Efficacy was consistent with previous 3L+ DLBCL findings.

KW - Clinical trial

KW - DLBCL

KW - epcoritamab

KW - outpatient

KW - relapsed/refractory

UR - https://www.scopus.com/pages/publications/105034634612

U2 - 10.1016/j.clml.2026.02.006

DO - 10.1016/j.clml.2026.02.006

M3 - Article

C2 - 41881714

AN - SCOPUS:105034634612

SN - 2152-2650

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

ER -

Epcoritamab Monotherapy as Outpatient Treatment for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Interim Results From EPCORE NHL-6

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this